Premium
Risk of transmission of human immunodeficiency virus (HIV) by heat‐ treated factor VIII concentrates in patients with severe hemophilia A
Author(s) -
Daenen S.,
Hoogeveen Y.,
Smit J.W.,
Imhoff G.W.,
Meer J.,
DeWolf J.T.,
Sibinga C.T.,
Halie R.M.
Publication year - 1987
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1046/j.1537-2995.1987.27688071700.x
Subject(s) - serology , medicine , virology , human immunodeficiency virus (hiv) , transmission (telecommunications) , immunology , risk factor , virus , viral disease , immunopathology , antibody , lymphocyte , immunodeficiency , sida , western blot , biology , immune system , electrical engineering , engineering , biochemistry , gene
Risk of transmission of human immunodeficiency virus (HIV) by heat‐ treated factor VIII concentrates in patients with severe hemophilia A At the change from unheated to heat‐treated Factor VIII concentrates for the treatment of hemophilia A, 17 severe adult hemophiliacs (mean monthly dose, 4927 IU) were evaluated prospectively for signs of infection with human immunodeficiency virus (HIV). Viral serology and lymphocyte subpopulations (OKT3, OKT4, and OKT8‐positive cells) were examined monthly for 1 year. One patient seroconverted for HIV in the enzyme‐linked immunoabsorbent assay but was positive on the Western blot analysis from the outset. There was a slight but significant increase in OKT4+ cells and OKT4/OKT8 ratio. These data suggest that heat‐treated Factor VIII concentrates even when used in large amounts have a low risk of transmitting HIV.